Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Hanny Al-Samkari, Vickie McDonald, Monica Carpenedo, Francesco Zaja, Nichola Cooper, Spero Cataland, Michael W Drazer, Yoshitaka Miyakawa, Marc Michel, Jaume Ayguasanosa, Janki Brahmbhatt, Lan Lan, Filip Matthijssens, Catherine M. Broome, Waleed Ghanima

Blood (2024) 144 (Supplement 1): 2570.1.

https://doi.org/10.1182/blood-2024-194816

Published: 2024

Journal Articles

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Waleed Ghanima, Howard A. Liebman, Yu Hu, Yoshitaka Miyakawa, Nichola Cooper, Güray Saydam, Marie Luise Hütter-Krönke, Sylvain Audia, Mengjie Yao, Ahmed Daak, Imene Gouia, Matias Cordoba, David J Kuter

Blood (2024) 144 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2024-200279

Published: 2024

Journal Articles

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Blood (2024) 144 (Supplement 1): 5.

https://doi.org/10.1182/blood-2024-199718

Published: 2024

Journal Articles

Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease

Aushna Rasool, Sinju Thomas, Asad Luqmani, Mamta Sohal, Steven Okoli, Simona Deplano, Christine Ademokun, Catriona Mactier, Nichola Cooper, D. Mark Layton

Blood (2024) 144 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2024-203179

Published: 2024

Journal Articles

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Nichola Cooper, David J Kuter, Henrik Frederiksen, Bing Han, Frederick Chen, Wilma Barcellini, Joan Cid, Catherine M. Broome, Míriam Vara, Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M Risitano, Sumit Sawhney, Quentin A. Hill, Deepthi Jayawardene, Remco Diab, Jing Zhao, Ahmed Daak

Blood (2024) 144 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2024-200325

Published: 2024

Journal Articles

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

David J Kuter, Tomas Jose Gonzalez Lopez, Karolin Trautmann-Grill, Mathias J. Rummel, Philip Young-Ill Choi, Alessandra Borchiellini, Muhlis Cem Ar, Huyen Tran, Tienan Zhu, Jae-Ho Yoon, Nichola Cooper, Thomas Stauch, Pinar Tarkun, Fabienne Le Gac, Alex Allepuz, Patrick Urban, Renxin Lin, Charlotte A. Bradbury

Blood (2024) 144 (Supplement 1): 710.

https://doi.org/10.1182/blood-2024-201418

Published: 2024

Journal Articles

T Cell Clonality in Paediatric Immune Thrombocytopenia

Michelle MH Tan, Amna Malik, Jiawen Wang, Clara Lo, Alice Hart, Nehal Joshi, Stuart Adams, Patrick Zhang, Katayoun Rezvani, Bing Zhang, Nichola Cooper

Blood (2024) 144 (Supplement 1): 550.

https://doi.org/10.1182/blood-2024-211065

Published: 2024

Journal Articles

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Adam Cuker, Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Roberto Abi Rached, David J Kuter

Blood (2023) 142 (Supplement 1): 5427.

https://doi.org/10.1182/blood-2023-180055

Published: 2023

Journal Articles

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Nichola Cooper, A.J. Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Michael D. Tarantino, Mamta Garg, Paula F Ypma, Vickie McDonald, Charles Percy, Milan Košťál, Isaac Goncalves, Lachezar H. Bogdanov, Terry B Gernsheimer, Remco Diab, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 685.

https://doi.org/10.1182/blood-2023-177808

Published: 2023

Journal Articles

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

Waleed Ghanima, Nichola Cooper, Sylvie Bozzi, Ahmed Daak, Imene Gouia, Matias Cordoba, Javier Barrio, Michael Kostikas, Owen Cooper, Howard A. Liebman

Blood (2023) 142 (Supplement 1): 2379.

https://doi.org/10.1182/blood-2023-179124

Published: 2023

Journal Articles

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

Michael D. Tarantino, A.J. Gerard Jansen, Nichola Cooper, Imene Gouia, Mengjie Yao, Ahmed Daak, David J Kuter

Blood (2023) 142 (Supplement 1): 690.

https://doi.org/10.1182/blood-2023-177811

Published: 2023

Journal Articles

The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0

James B. Bussel, Nichola Cooper, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama, Ming Hou, Donald Arnold, Cristina Santoro, Francesco Zaja, Barbara Lovrencic, Mervyn Morgan, Leron Lahav, Michal Winograd, Jennifer MacWhirter - DiRaimo, Tom Bailey, Moyra Aziz, Roberto Abi Rached, Caroline Kruse

Blood (2023) 142 (Supplement 1): 1212.

https://doi.org/10.1182/blood-2023-188527

Published: 2023

Journal Articles

Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review

Blood (2023) 142 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2023-179448

Published: 2023

Journal Articles

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

Hanny Al-Samkari, Wilma Barcellini, Nichola Cooper, Waleed Ghanima, Marc Michel, Raymond SM Wong, Francesco Zaja, Fengkui Zhang, Patrick Urban, Alex Allepuz, Justyna Fronczek-Sokol, Jens Haenig, Pascal Edrich, Adam Cuker

Blood (2023) 142 (Supplement 1): 5456.

https://doi.org/10.1182/blood-2023-180647

Published: 2023

Journal Articles

The role of CD8 + T-cell clones in immune thrombocytopenia

Blood (2023) 141 (20): 2417–2429.

https://doi.org/10.1182/blood.2022018380

Published: 2023

Includes: Multimedia, Supplemental data

Journal Articles

Characterisation of Platelet Sensitivity in Severe COVID-19

Rocel C. Saputil, Joanne L. Dunster, Neline Kriek, Yunchuan Ding, Michelle M.H. Tan, Emma Thorley, Clio Pillay, Asad Charania, Margarita Dominguez-Villar, Wayne A. Mitchell, Amna Malik, Jonathan M. Gibbins, Nichola Cooper

Blood (2022) 140 (Supplement 1): 11263–11264.

https://doi.org/10.1182/blood-2022-169954

Published: 2022

Journal Articles

Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review

Sara Stefani, Rocel C. Saputil, Michelle MH Tan, Noora Buti, Deena Paul, Naghma Rizvi, Vashti Ragoonanan, Emma Thorley, Ariam Teklemichael, Camelia Vladescu, Amna Malik, Christine Ademokun, Alice C J Hart, Richard Szydlo, George Adams, James B. Bussel, A.J. Gerard Jansen, Nichola Cooper

Blood (2022) 140 (Supplement 1): 5546–5548.

https://doi.org/10.1182/blood-2022-167614

Published: 2022

Journal Articles

Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity

Rocel C. Saputil, Joanne L. Dunster, Neline Kriek, Yunchuan Ding, Anuradha Bhide, Alice C J Hart, Michelle MH Tan, Emma Thorley, Ariam Teklemichael, Wayne A. Mitchell, Amna Malik, Jonathan M. Gibbins, Nichola Cooper

Blood (2022) 140 (Supplement 1): 2691–2692.

https://doi.org/10.1182/blood-2022-167798

Published: 2022

Journal Articles

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Vickie McDonald, Charlotte Bradbury, Kate Talks, Gillian Lowe, Sue Pavord, Gillian Evans, Manoharan Andiappan, Darcie Sandschafer, Vitor Jose De Sousa Barbosa, Lorraine Stephens, Nichola Cooper

Blood (2022) 140 (Supplement 1): 2678–2680.

https://doi.org/10.1182/blood-2022-157698

Published: 2022

Journal Articles

CD8 + TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia

Blood (2022) 140 (Supplement 1): 2209–2210.

https://doi.org/10.1182/blood-2022-166348

Published: 2022

NARROW

Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)

Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

T Cell Clonality in Paediatric Immune Thrombocytopenia

Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia

The Effects of Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, on Bleeding Symptoms and Health-Related Quality of Life in Patients with Immune Thrombocytopenia

The Lack of Tolerable Treatments Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0

Treatment of Critical Bleeding Events in Patients with Immune Thrombocytopenia: A Systematic Review

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA)

The role of CD8 + T-cell clones in immune thrombocytopenia

Characterisation of Platelet Sensitivity in Severe COVID-19

Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review

Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity

Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

CD8 + TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only